Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08065010 in healthy adult participants
NCT07235163Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-08065010 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (14 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at 7 months, Number of Participants With Clinically Significant Laboratory Abnormalities at 7 months and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
PF-08065010
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07235163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235163.